Details

Autor(en) / Beteiligte

• Aoyagi, Kyoko
• Higuchi, Yoshinori
• Matsunaga, Shigeo
• Serizawa, Toru
• Yomo, Shoji
• Aiyama, Hitoshi
• Nagano, Osamu
• Kondoh, Takeshi
• Kenai, Hiroyuki
• Shuto, Takashi
• Kawagishi, Jun
• Jokura, Hidefumi
• Sato, Sonomi
• Nakazaki, Kiyoshi
• Nakaya, Kotaro
• Hasegawa, Toshinori
• Kawashima, Mariko
• Kawai, Hideya
• Yamanaka, Kazuhiro
• Nagatomo, Yasushi
• Yamamoto, Masaaki
• Sato, Yasunori
• Aoyagi, Tomoyoshi
• Matsutani, Tomoo
• Iwadate, Yasuo

Titel

Impact of breast cancer subtype on clinical outcomes after Gamma Knife radiosurgery for brain metastases from breast cancer: a multi-institutional retrospective study (JLGK1702)

Ist Teil von

• Breast cancer research and treatment, 2020-11, Vol.184 (1), p.149-159

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2020

Quelle

Springer LINK 全文期刊数据库

Beschreibungen/Notizen

• Introduction Brain metastasis (BM) is one of the most important issues in the management of breast cancer (BC), since BMs are associated with neurological deficits. However, the importance of BC subtypes remains unclear for BM treated with Gamma Knife radiosurgery (GKS). Thus, we conducted a multicenter retrospective study to compare clinical outcomes based on BC subtypes, with the aim of developing an optimal treatment strategy. Methods We studied 439 patients with breast cancer and 1–10 BM from 16 GKS facilities in Japan. Overall survival (OS) was analyzed by the Kaplan–Meier method, and cumulative incidences of systemic death (SD), neurologic death (ND), and tumor progression were estimated by competing risk analysis. Results OS differed among subtypes. The median OS time (months) after GKS was 10.4 in triple-negative (TN), 13.7 in Luminal, 31.4 in HER2, and 35.8 in Luminal-HER2 subtype BC ( p  < 0.0001). On multivariate analysis, poor control of the primary disease (hazard ratio [HR] = 1.84, p  < 0.0001), active extracranial disease (HR = 2.76, p  < 0.0001), neurological symptoms (HR 1.44, p  = 0.01), and HER2 negativity (HR = 2.66, p  < 0.0001) were significantly associated with worse OS. HER2 positivity was an independent risk factor for local recurrence ( p  = 0.03) but associated with lower rates of ND ( p  = 0.03). TN histology was associated with higher rates of distant brain failure ( p  = 0.03). Conclusions HER2 positivity is related to the longer OS after SRS; however, we should pay attention to preventing recurrence in Luminal-HER2 patients. Also, TN patients require meticulous follow-up observation to detect distant metastases and/or LMD.